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There is a complex interaction between public health and 
private health care in South Africa. Only 14.1% of the 
population has comprehensive access to private-sector 
health care on a regular basis, through medical aid schemes. 
Yet private health care is the dominant vehicle for both the 
financing and provision of health care in the country.1 Generic 
substitution in this sector, therefore, has the potential to cut 
medication costs significantly.
The Medicines and Related Substances Control Amendment 
Act No. 90 of 1997 (hereinafter referred to as ‘The Act’) was 
tabled in Parliament in May 1997.2 It was designed to enable 
the government to undertake a variety of actions in order to 
provide a supply of more affordable medicines.3 This study 
examines only one of the repercussions of the law, namely 
generic substitution of a branded drug. Although generics are 
the first choice in the public sector, the beneficiaries of medical 
aid schemes, as medical consumers, have the option whether or 
not to choose a generic medicine.
Mandatory generic substitution
The Act, implemented on 2 May 2003, states that pharmacists 
are to inform all private patients buying medicines by 
prescription about the benefits of generic alternatives. The 
pharmacist is required by law to dispense the generic, unless 
the patient (or the patient’s doctor) expressly refuses the 
substitution, or the price of the generic is higher than that of 
the branded product. 
The implementation of the Act required the assistance 
of many role players, including the Department of Health, 
medical practitioners, pharmacists, and administrators of 
medical aid schemes.
Implications of generic substitution
Generic substitution is a contentious matter because it has 
ethical and economic implications. According to the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) 
Agreement, patents for medicines are treated in the same way 
as those for any other merchandise or commodity.4 Patents 
provide the brand drug manufacturer with the legal means to 
prevent others from making, using or selling the invention and 
are used to provide incentives for research and development 
into new ideas. 
The government has the delicate role of striking a balance 
between protecting the intellectual property of the developers 
of blockbuster drugs, and ensuring affordable medication. 
However, in order that pharmaceutical companies continue to 
invest in research and development in South Africa, economic 
viability needs to be ensured.  Without patent protection there 
is little incentive for the pharmaceutical industry to develop 
new drugs.5 This places the health of future generations 
in jeopardy, not only because of the lack of research and 
development, but also because of the drain of resources that 
will accompany it.5
However, the Act should be seen in context. South Africa is 
not comparable with the rest of the developed world owing 
to differences in infrastructure, budgets and health policy, 
as well as the burden of disease profiles. Cheaper drugs are 
not necessarily equated with better health care. Supporting 
structures such as medical doctors, nurses, hospitals and 
researchers, not to mention general infrastructure influences 
(such as electricity and water) also have a bearing on the extent 
to which minimising drug costs can contribute to lower health 
care costs.
Materials and methods
Tenormin was chosen as the study drug because it has been 
on the market since 1970.6 As a beta-blocker, used for the 
treatment of hypertension, it benefits from widespread use 
across all population groups in South Africa and is taken on a 
daily basis. It was compared with three generics, namely, Ten-
Bloka, Rolab Atenolol and Adco-Atenolol.
Discovery Health was used as the medical aid scheme 
because it is the largest open medical aid scheme in the 
country, with 22.8% of the market share.7 A year prior to the 
implementation of the Act was chosen as the starting point 
of the study because a trend in the claiming patterns could 
be ascertained within this time period. The time frame under 
study ended on 30 April 2004, just before the implementation 
of the new pricing policies.
Because of the fact that all the medicines being studied 
have been on the market for at least 10 years, it can safely be 
presumed that they have become established in that segment 
of the market. By obtaining a figure of the market segment thus 
secured, a true reflection of any effects on the market could be 
illustrated.
Results
The results were initially studied using descriptive statistics. 
Thereafter, statistical models were applied to determine the 
significance of the changes.
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   Fig. 1. illustrates the following information: (i) Tenormin 
had already lost a great deal of its market share a year before 
the implementation of the law; (ii) Ten-Bloka is the market 
leader in providing Atenolol in the private sector, both before 
and after implementation of the law;  (iii) the market share of 
Rolab-Atenolol remained low over the 2-year period examined; 
and (iv) visually, there appears to be a change in trend at the 
end of 2002.
The first step in the treatment of the data consisted of 
calculating the ratio of branded to generic drugs claimed 
at the medical aid scheme. This captured the true nature of 
the trend and allowed for changes in member numbers. In 
addition, it allowed for the overall impact of the generic law 
to be ascertained since generics as a whole were compared 
with the branded drug. Using the Auto Regressive Integrated 
Moving Averages (ARIMA) model, a significant change in 
drug-claiming patterns occurred between December 2002 and 
January 2003, 4 months before promulgation of the law. The 
probability that the change in claiming patterns was due to 
chance is very low (p = 0.0002).
In their support for generic substitution Discovery Health 
introduced a new policy in January 2004. According to this 
policy the 10% levy would be waived on the medication bill 
of beneficiaries who opted for generic drugs. This aimed 
to increase the use of generic drugs in an effort to diminish 
health care costs. Because of the fact that this was a known 
intervention, the ARIMA model was applied to the data at 
that point. The analysis revealed that the intervention was 
not significant (t = 1.71; p = 0.56). However, owing to the fact 
that the analysis of the effect of the intervention of Discovery 
occurred over a short period of time, the results were not 
entirely conclusive.
Discussion
The road to the implementation of the Act was tumultuous 
since nearly 7 years elapsed between the time it was tabled 
and the time it was implemented. The draft regulations of the 
Act were published in the South African Government Gazette 
on 1 June 2001.8 Between this time and October 2002 discourse 
took place between the government and the pharmaceutical 
industry. By October 2002 the law had been finalised, and 
no further requests for commentary were made. On 28 
March 2003, the Medicines and Related Substances Control 
Amendment Act was signed by President Thabo Mbeki.9 
Owing to the protracted course of the implementation of the 
law, it is surmised that the premature increase in generic claims 
was due to the certainty that the law would be implemented. 
Nevertheless, generic substitution did continue to increase 
after the law was implemented. However the intervention by 
Discovery Health to promote generic substitution did not affect 
claiming patterns, and was subsequently withdrawn.
Conclusions
The aims of the Act have been fulfilled. The greatest increase 
in medical aid claims for generic drugs occurred prematurely, 
in anticipation of the implementation of the law. However, the 
support offered by Discovery Health to deter members from 
buying branded drugs did not yield significant results.
This study was conducted at the University of the 
Witwatersrand Medical School towards an MSc (Med) in 
Pharmacotherapy.
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Fig. 1. The trend in claiming patterns from May 2002 to April 2004 for 
Tenormin and three generics.
Su
m
 o
f c
la
im
an
ts 
pe
r 1
00
0
January 2007, Vol. 97, No. 1  SAMJ
pg 63-64.indd   64 12/18/06   5:17:36 PM
